Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
The purpose of this study is to determine the safety and efficacy of different doses of
 CAT-2003 in patients with hyperlipidemia when CAT-2003 is taken for 4 weeks. The study will
 evaluate effects of CAT-2003 on (1) fasting triglycerides and non-HDL-C in patients with
 moderate hypertriglyceridemia and (2) fasting LDL-C levels in combination with a statin in
 patients with hypercholesterolemia who are on a statin.
Inclusion Criteria:

 -  Between 18 and 69 years at Screening

 -  Hypertriglyceridemia (TG ≥ 200 mg/dL and < 500 mg/dL and non-HDL-C ≥ 100 mg/dL and <
 220 mg/dL) OR

 -  Hypercholesterolemia (LDL-C ≥ 100 mg/dL and < 190 mg/dL and TG value < 200 mg/dL) plus
 a stable dose of statin for at least 4 weeks prior to Screening.

 -  Body mass index (BMI) ≤ 45 kg/m2

 Exclusion Criteria:

 -  History of any major cardiovascular event within 6 months of Screening

 -  Type I diabetes mellitus

 -  Any condition that may predispose the patient to secondary hyperlipidemia, such as
 uncontrolled hypothyroidism

 -  Any statin at the highest approved dose

 -  Non-statin lipid-altering drugs other than cholesterol absorption inhibitors.

 -  Active peptic ulcer disease or a history of muscle disease or myopathy